New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 30mg equivalent to 27 mg oxycodone base - modified release tablet - 30 mg - active: oxycodone hydrochloride 30mg equivalent to 27 mg oxycodone base excipient: lactose monohydrate magnesium stearate methacrylic acid copolymer opadry brown ys-1-16518-a povidone purified talc stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 60mg - modified release tablet - 60 mg - active: oxycodone hydrochloride 60mg excipient: ammonio methacrylate copolymer lactose monohydrate magnesium stearate opadry red 15b25501 povidone purified talc purified water stearyl alcohol triacetin - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 10mg;   - capsule - 10 mg - active: oxycodone hydrochloride 10mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - the management of opioid responsive, moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 20mg;   - capsule - 20 mg - active: oxycodone hydrochloride 20mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose sodium laurilsulfate titanium dioxide - the management of opioid responsive, moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 5mg;   - capsule - 5 mg - active: oxycodone hydrochloride 5mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose sodium laurilsulfate sunset yellow fcf titanium dioxide - the management of opioid responsive, moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 1 mg/ml - oral solution - 5 mg/5ml - active: oxycodone hydrochloride 1 mg/ml excipient: citric acid monohydrate hydrochloric acid hypromellose purified water saccharin sodium sodium benzoate sodium citrate dihydrate sodium hydroxide - the management of opioid responsive, moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 10 mg/ml - solution for injection - 10 mg/ml - active: oxycodone hydrochloride 10 mg/ml excipient: citric acid monohydrate hydrochloric acid purified water sodium chloride sodium citrate dihydrate sodium hydroxide - the management of opioid-responsive moderate to severe pain

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - oxycodone hydrochloride 50 mg/ml equivalent to oxycodone base 45 mg - solution for injection - 50 mg/ml - active: oxycodone hydrochloride 50 mg/ml equivalent to oxycodone base 45 mg excipient: citric acid monohydrate hydrochloric acid nitrogen sodium chloride sodium citrate sodium hydroxide water for injection - the management of opioid-responsive moderate to severe pain.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ciclosporin 50 mg/ml - solution for infusion - 250 mg/5ml - active: ciclosporin 50 mg/ml excipient: ethanol polyoxyl 35 castor oil - solid organ transplantation prevention of graft rejection following kidney, liver, heart, combined heart-lung, lung or pancreas allogeneic transplantations. treatment of transplant rejection in patients previously receiving other immunosuppressive agents. bone marrow transplantation prevention of graft rejection following bone marrow transplantation. prevention or treatment of graft-versus-host disease (gvhd).

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base - solution for injection - 0.05 mg/ml - active: octreotide acetate 0.056 mg/ml equivalent to 0.05 mg/ml octreotide base excipient: lactic acid mannitol sodium bicarbonate water for injection